Request Demo

Last update 23 Jan 2025

Dysentery, Amebic

Last update 23 Jan 2025

Basic Info

Synonyms

AMEBIC DYSENTERY, Amebiases, Intestinal, Amebiasis

+ [71]

Introduction

DYSENTERY caused by intestinal amebic infection, chiefly with ENTAMOEBA HISTOLYTICA. This condition may be associated with amebic infection of the LIVER and other distant sites.

Drugs associated with Dysentery, Amebic

Ornidazole

Target-

Mechanism-

Active Org.

Huadong Medicine (xi'an) Bodyguard Pharmaceutical Co., Ltd.

Originator Org.

Huadong Medicine (xi'an) Bodyguard Pharmaceutical Co., Ltd.

Active Indication

Amebiasis [+3]

Inactive Indication

Dysentery, Amebic [+2]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date01 Jan 2001

Doxycycline Hyclate

Target

30S subunit

Mechanism

30S subunit inhibitors

Active Org.

CHARTWELL RX SCIENCES LLC [+4]

Originator Org.

Pfizer Inc.

Active Indication

Anthrax [+25]

Inactive Indication

Lyme Disease [+2]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date05 Dec 1967

Nifuratel

Target-

Mechanism-

Active Org.-

Originator Org.-

Active Indication

Bacterial Vaginosis [+5]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date01 Jan 1960

Clinical Trials associated with Dysentery, Amebic

CTRI/2024/07/070451

/ Not yet recruitingNot ApplicableIIT

A clinical study of Zaheer(Dysentery) and comparative evaluation of Sharbat Belgiri and Tiryaq e Pechish in its management - Nil

Start Date19 Jul 2024

Sponsor / Collaborator-

CTRI/2023/09/058088

/ Not yet recruitingPhase 2

To study the effectiveness of Aegle marmelos in clinical practice. - NIL

Start Date06 Oct 2023

Sponsor / Collaborator-

CTR20212653

/ CompletedNot Applicable

奥硝唑片在空腹及餐后条件下的人体生物等效性试验

[Translation] Bioequivalence study of ornidazole tablets in humans under fasting and fed conditions

主要研究目的考察健康受试者在空腹及餐后条件下，单次口服1片由山东鲁抗医药集团赛特有限责任公司生产的奥硝唑片（受试制剂T，规格：0.5g）与相同条件下单次口服1片由OrPha Swiss GmbH持证的奥硝唑片（参比制剂R，商品名：Tiberal®，规格：0.5g）的药动学特征，评价两制剂的生物等效性，为该受试制剂一致性评价提供依据。次要研究目的观察健康受试者在空腹及餐后条件下单次口服0.5g的受试制剂奥硝唑片（规格：0.5g）与参比制剂奥硝唑片（商品名：Tiberal®，规格：0.5g）的安全性。

[Translation]

Main study objectives To investigate the pharmacokinetic characteristics of a single oral tablet of ornidazole tablets (test preparation T, specification: 0.5g) produced by Shandong Lukang Pharmaceutical Group Saite Co., Ltd. and a single oral tablet of ornidazole tablets (reference preparation R, trade name: Tiberal®, specification: 0.5g) certified by OrPha Swiss GmbH under the same conditions in healthy subjects under fasting and postprandial conditions, evaluate the bioequivalence of the two preparations, and provide a basis for the consistency evaluation of the test preparation. Secondary study objectives To observe the safety of a single oral administration of 0.5g of the test preparation ornidazole tablets (specification: 0.5g) and the reference preparation ornidazole tablets (trade name: Tiberal®, specification: 0.5g) in healthy subjects under fasting and postprandial conditions.

Start Date31 Oct 2021

Sponsor / Collaborator

Shandong Lukang Pharmaceutical Group Saite Co., Ltd.

100 Clinical Results associated with Dysentery, Amebic

100 Translational Medicine associated with Dysentery, Amebic

0 Patents (Medical) associated with Dysentery, Amebic

2,181

Literatures (Medical) associated with Dysentery, Amebic

08 Jan 2025·The American Journal of Tropical Medicine and Hygiene

Fulminant Amoebic Colitis

Article

Author: Cataño, Juan Carlos ; Montoya, Valentina

20 Dec 2024·The Tokai journal of experimental and clinical medicine

Difficulty Confirming the Diagnosis of Amoebic Enteritis.

Article

Author: Suzuki, Hidekazu ; Ueda, Takashi ; Fujisawa, Mia ; Teramura, Erika ; Arase, Yoshitaka ; Sato, Hirohiko ; Deguchi, Ryuzo ; Sano, Masaya ; Matsushima, Masashi ; Kagawa, Tatehiro

Amoebic dysentery is designated a Category 5 disease under the Infectious Disease Control Law in Japan, with approximately 1,000 cases reported annually. About 10% of these are cases of invasive amoebic dysentery, 90% of which have an asymptomatic course and are often discovered incidentally, and there is concern that the number of undiagnosed cases is increasing since the reagent for that blood antibody test was discontinued in 2017. Invasive amoebic dysentery often causes ulcerative lesions that affect the cecum and rectum predominantly, but eradication of amoebic dysentery is possible with proper diagnosis and treatment. However, there have been cases in which delayed diagnosis and treatment have resulted in fulminant forms of colorectal ulceration, including perforated peritonitis and amoebic liver abscesses. In this report, the importance of the diagnosis and treatment of this disease is reiterated, and a case that was difficult to diagnose is presented.

01 Nov 2024·Journal of Surgical Case Reports

Fulminant amoebic colitis: a challenging diagnosis for the surgeon

Article

Author: Hernández-Montiel, Erika ; Núñez-Venzor, Alejandra ; Solis-Coronado, Orlando ; Alvarez-Bautista, Francisco E ; Betancourt-Ferreyra, Jessica Jazmín ; Barrón-Díaz, David Rafael ; Meza-Hernández, Javier ; Trejo-Ávila, Mario

AbstractFulminant amoebic colitis is a rare complication of amoebiasis that carries a high mortality rate. Its diagnosis is challenging and requires a high index of suspicion, and its early recognition is a priority to provide timely medical and surgical treatment. We present the case of a male patient who came to the emergency department with unspecific clinical presentation of abdominal pain, systemic inflammatory response and imaging study showing intestinal perforation of the right colon. Fecal peritonitis and perforation at the level of the hepatic flexure were observed, so a right hemicolectomy with terminal ileostomy was performed. Despite adequate medical and surgical treatment, the patient presented progressive deterioration and died. Colon perforation due to Entamoeba histolytica was the final diagnosis.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Dysentery, Amebic

Basic Info

Related

Analysis